GSC The List

Post Reply
Forum Home > I > IBS/IBD + (See Also BOWEL DISORDERS)

[email protected]
Site Owner
Posts: 1174

Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. (full – 2011) http/

Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full – 2011) http/

The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. (full – 2011) http/

A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. (full – 2011) http/

Pharmacogenetic Trial of a Cannabinoid Agonist Shows Reduced Fasting Colonic Motility in Patients with Non-Constipated Irritable Bowel Syndrome. (full – 2011) http/

Cannabis use amongst patients with inflammatory bowel disease. (abst – 2011) http/

Role of cannabinoid receptors and RAGE in inflammatory bowel disease. (abst – 2011) http/

Cannabis Use Common Among Patients With Inflammatory Bowel Disease, Study Says (news – 2011) http/

Irritable bowel syndrome: a dysfunction of the endocannabinoid system? (full – 2012) http/

The Gastrointestinal Pharmacology of Cannabinoids: Focus on Motility. (full – 2012) http/

Genetic Epidemiology and Pharmacogenetics in Irritable Bowel Syndrome. (full - 2012) http/

Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome (full – 2012) http/

Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. (full – 2012) http/

Gut microbiota and the development of obesity. (full – 2012) http/

The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. (abst – 2012) http/

Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview. (abst – 2012) http/

The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. (abst – 2012) http/

Agents that act luminally to treat diarrhoea and constipation. (abst – 2012) http/

Cannabis Finds Its Way into Treatment of Crohn's Disease. (full – 2013) http/

Role of endogenous cannabinoid system in the gut. (full – 2013) http/

Irritable Bowel Syndrome and Migraine: Bystanders or Partners? (full – 2013) http/

Endocannabinoid and Cannabinoid-Like Fatty Acid Amide Levels Correlate with Pain-Related Symptoms in Patients with IBS-D and IBS-C: A Pilot Study. (full – 2013) http/

Cannabinoid Receptor 1 Gene and Irritable Bowel Syndrome: Phenotype and Quantitative Traits. (full – 2013) http/

Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis. (full – 2013) http/

Industrial hemp decreases intestinal motility stronger than indian hemp in mice. (link to PDF – 2013) http/

Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. (abst – 2013) http/

Preventive and therapeutic oral administration of the pentacyclic triterpene α,β-amyrin ameliorates dextran sulfate sodium-induced colitis in mice: The relevance of cannabinoid system. (abst – 2013) http/

Cannabidiol in inflammatory bowel diseases: a brief overview. (abst – 2013) http/

Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model. (abst – 2013) http/

Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract (abst – 2013) http/

Decreased Enteric Fatty Acid Amide Hydrolase Activity is Associated with Colonic Inertia in Slow Transit Constipation (abst – 2013) http/

Marijuana use patterns among patients with inflammatory bowel disease. (abst – 2013) http/

Still Believe Nature Got It Wrong? Top 10 Health Benefits of Marijuana (news – 2013) http/

Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System. (full – 2014) http/

Association of cannabinoid type 1 receptor and fatty acid amide hydrolase genetic polymorphisms in Chinese patients with irritable bowel syndrome. (abst – 2014) http/

Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides. (abst – 2014) http/

Switching cannabinoid response from CB2 agonists to FAAH inhibitors. (abst – 2014) http/

Toward modulation of the endocannabinoid system for treatment of gastrointestinal disease: FAAHster but not "higher". (abst – 2014) http/

Vagal anandamide signaling via cannabinoid receptor 1 contributes to luminal 5-HT modulation of visceral nociception in rats. (abst – 2014) http/

Ultramicronized palmitoylethanolamide normalizes intestinal motility in a murine model of post-inflammatory accelerated transit: involvement of CB1 receptors and TRPV1. (abst – 2014) http/

The endocannabinoid anandamide regulates the peristaltic reflex by reducing neuroneuronal and neuro-muscular neurotransmission in ascending myenteric reflex pathways in rats. (abst – 2014) http/

Cannabis for inflammatory bowel disease. (abst – 2014) http/

Clinical endocannabinoid deficiency (CECD) revisited: Can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? (abst – 2014) http/

Potential therapeutic applications of cannabinoids in gastrointestinal and liver diseases: Focus on Δ9-tetrahydrocannabinol pharmacology (abst – 2014) http/

(Mo1121) Cannabinoid Use Decreases ED Utilization in a Gastroenterology Clinic Population (abst – 2014)


(Mo1122) Prevalence and Characterization of Cannabinoid Use in Patients With Gastrointestinal Disorders (abst – 2014) http/

Palmitoylethanolamide, a naturally-occurring lipid, is an orally effective intestinal anti-inflammatory agent (abst – 2014)

Medical Marijuana for Digestive Disorders: High Time to Prescribe? (abst – 2014)

Cannabinoids Alleviate Experimentally Induced Intestinal Inflammation by Acting at Central and Peripheral Receptors (abst – 2014)

N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N palmitoylethanolamine levels and counteracts murine colitis (abst – 2014)

Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome (abst – 2014)

Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice (abst – 2014)

No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects (abst – 2015)

A Gut Microbial Metabolite of Linoleic Acid, 10-Hydroxy-cis-12-octadecenoic Acid, Ameliorates Intestinal Epithelial Barrier Impairment Partially via GPR40-MEK-ERK Pathway (abst – 2015)

AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally-restricted manner (abst – 2015)

March 16, 2015 at 3:37 AM Flag Quote & Reply

This topic is closed, no additional posts are allowed.